Pitisuttithum Punnee, Rerks-Ngarm Supachai, O'Connell Robert J, Kim Jerome H, Excler Jean-Louis
Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand.
Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand.
Vaccines (Basel). 2013 Aug 14;1(3):348-66. doi: 10.3390/vaccines1030348.
Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.
泰国开展的RV144疗效试验带来了HIV疫苗研发的最新进展，同时人们对风险的免疫关联也有了更深入的了解。流行病学数据表明，CRF01_AE在东南亚地区仍然占主导地位，并且由于人类接触增加，特别是在大型城市中心、旅游地点和公共基础设施场所，它正在中国传播，出现了越来越多的循环重组形式。研发针对CRF01_AE的疫苗是该地区的优先事项。应积极研发针对不断扩大的B/E或BCE重组形式的亚洲HIV疫苗。仍然存在的一个主要挑战是在该地区的异性恋人群中开展疗效试验。男男性行为者是亚洲未来疗效试验的主要目标人群。在疗效试验中也可以考虑将HIV疫苗与其他预防方式相结合。只有通过开展大规模疗效试验、跨学科团队、国际合作以及强有力的政治和社区承诺，这些新途径才有可能实现。
